These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8130888)

  • 1. Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man.
    Gallacher SJ; Cowan RA; Fraser WD; Logue FC; Jenkins A; Boyle IT
    Eur J Endocrinol; 1994 Feb; 130(2):141-5. PubMed ID: 8130888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effect of oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol on markers of bone metabolism.
    Joffe P; Ladefoged SD; Cintin C; Jensen LT; Hyldstrup L
    Nephrol Dial Transplant; 1994; 9(5):524-31. PubMed ID: 8090332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study.
    Ardawi MS; Nasrat HA; BA'Aqueel HS
    Eur J Endocrinol; 1997 Oct; 137(4):402-9. PubMed ID: 9368509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB; Fraher LJ
    Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients.
    Al-Hilali N; Al-Humoud H; Al-Helal B; Al-Azmi M; Al-Kandari NH; Johny KV
    Ther Apher Dial; 2008 Apr; 12(2):137-42. PubMed ID: 18387162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
    Malberti F; Surian M; Cosci P
    Nephrol Dial Transplant; 1992; 7(8):822-8. PubMed ID: 1325615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteocalcin in primary hyperparathyroidism: short-term effect of surgery.
    Minisola S; Scarnecchia L; Scarda A; Bigi F; Tabolli S; Valtorta C; Mazzuoli G
    Miner Electrolyte Metab; 1988; 14(4):201-7. PubMed ID: 3264876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperparathyroidism and low serum osteocalcin despite vitamin D replacement in primary biliary cirrhosis.
    Fonseca V; Epstein O; Gill DS; Menon RK; Thomas M; McIntyre N; Dandona P
    J Clin Endocrinol Metab; 1987 May; 64(5):873-7. PubMed ID: 3494037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum osteocalcin levels in primary hyperparathyroidism.
    Pietschmann P; Niederle B; Anvari A; Woloszczuk W
    Klin Wochenschr; 1991 May; 69(8):351-3. PubMed ID: 1886398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procollagen type 1 C-terminal extension peptide serum levels following parathyroidectomy in hyperparathyroid patients.
    Coen G; Mazzaferro S; De Antoni E; Chicca S; DiSanza P; Onorato L; Spurio A; Sardella D; Trombetta M; Manni M
    Am J Nephrol; 1994; 14(2):106-12. PubMed ID: 8080002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
    Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery.
    Minisola S; Romagnoli E; Scarnecchia L; Rosso R; Pacitti MT; Scarda A; Mazzuoli G
    Eur J Endocrinol; 1994 Jun; 130(6):587-91. PubMed ID: 8205259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A; Sabry A; Bawadekji H; Alsaran K
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
    Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
    Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.